Ultrasound Contrast Agents Market Share

Geographically, the ultrasound contrast agents market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to dominate majority revenue share by 2036, owing to increasing necessity for advanced diagnosis methods to detect various disease indications such as neurological disorders, cancer, cardiovascular diseases, and others. Moreover, the developing healthcare sector, supported by the increasing government investment in the public healthcare system is also expected to boost the market growth.

The ultrasound contrast agents market in the North America is evaluated to occupy the largest share in terms of revenue, by the end of 2030, owing to the increasing prevalence of cardiovascular diseases in the region. According to American Heart Association, in 2017, CVD has been listed as one of the most prominent underlying causes of death in the United States, which accounted for around 74% of all deaths. As per the data by the CDC, one person dies every 36 seconds in the United States from cardiovascular diseases. Such an increasing number of CVD cases in the United States has significantly increased the demand for ultrasound examination in this region, which is further expected to drive the ultrasound contrast agents market in the region.